Payment overview · 2025
General Payments
$499.53
23 reported records · 8 companies
Healthcare provider profile · identity verified
Zeba Barlas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1285642546
Verified facts
What the public records show
CMS Open Payments records show Zeba Barlas, M.D. received $499.53 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.78 | 32.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.69 | 24.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.78 | 20.6% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.42 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.42 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.90 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.92 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.62 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $499.53 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.69 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $102.78 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.50 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.80 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.24 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 118 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1320 | 432 |
| Amlodipine Besylate | Amlodipine Besylate | 895 | 284 |
| Gabapentin | Gabapentin | 478 | 167 |
| Metformin Hcl | Metformin Hcl | 446 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 446 | 168 |
| Hydrochlorothiazide | Hydrochlorothiazide | 429 | 137 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 406 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 136 |
| Furosemide | Furosemide | 367 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 105 |
| Lisinopril | Lisinopril | 303 | 110 |
| Losartan Potassium | Losartan Potassium | 293 | 96 |
| Omeprazole | Omeprazole | 293 | 96 |
| Metformin Hcl Er | Metformin Hcl | 283 | 95 |
| Alendronate Sodium | Alendronate Sodium | 246 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 76 |
| Azithromycin | Azithromycin | 225 | 165 |
| Prednisone | Prednisone | 218 | 136 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 215 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 209 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 75 |
| Mirtazapine | Mirtazapine | 197 | 66 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 192 | 144 |
| Carvedilol | Carvedilol | 190 | 65 |
| Simvastatin | Simvastatin | 170 | 63 |
| Tramadol Hcl | Tramadol Hcl | 167 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 50 |
| Ibuprofen | Ibuprofen | 157 | 69 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 146 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 136 | 58 |
| Jardiance | Empagliflozin | 133 | 44 |
| Clonidine Hcl | Clonidine Hcl | 131 | 43 |
| Fenofibrate | Fenofibrate Nanocrystallized | 129 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 53 |
| Eliquis | Apixaban | 118 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 23 |
| Nifedipine Er | Nifedipine | 112 | 40 |
| Cefdinir | Cefdinir | 111 | 84 |
| Sertraline Hcl | Sertraline Hcl | 110 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 36 |
| Celecoxib | Celecoxib | 108 | 36 |
| Baclofen | Baclofen | 105 | 48 |
| Allopurinol | Allopurinol | 104 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 66 |
| Ozempic | Semaglutide | 97 | 17 |
| Meloxicam | Meloxicam | 94 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 35 |
| Tradjenta | Linagliptin | 91 | 25 |
| Glipizide Er | Glipizide | 90 | 29 |
| Montelukast Sodium | Montelukast Sodium | 90 | 25 |
| Trazodone Hcl | Trazodone Hcl | 82 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 56 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 78 | 34 |
| Meclizine Hcl | Meclizine Hcl | 76 | 30 |
| Alprazolam | Alprazolam | 75 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 71 | 58 |
| Farxiga | Dapagliflozin Propanediol | 70 | 24 |
| Spironolactone | Spironolactone | 69 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 21 |
| Mupirocin | Mupirocin | 68 | 28 |
| Clonazepam | Clonazepam | 67 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 25 |
| Potassium Chloride | Potassium Chloride | 63 | 17 |
| Enalapril Maleate | Enalapril Maleate | 62 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 22 |
| Lactulose | Lactulose | 61 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 21 |
| Donepezil Hcl | Donepezil Hcl | 56 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 53 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 21 |
| Atenolol | Atenolol | 51 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Fluconazole | Fluconazole | 51 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 16 |
| Levofloxacin | Levofloxacin | 49 | 37 |
| Finasteride | Finasteride | 46 | 20 |
| Valsartan | Valsartan | 46 | 17 |
| Latanoprost | Latanoprost | 45 | 14 |
| Sucralfate | Sucralfate | 45 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 45 | 13 |
| Hydrocortisone | Hydrocortisone | 43 | 27 |
| Levetiracetam | Levetiracetam | 41 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 17 |
| Metronidazole | Metronidazole | 40 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 12 |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Glimepiride | Glimepiride | 39 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Terconazole | Terconazole | 38 | 28 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | suppressed |
| Nystatin | Nystatin | 36 | 23 |
| Acyclovir | Acyclovir | 35 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Famotidine | Famotidine | 32 | 15 |
| Methylprednisolone | Methylprednisolone | 32 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 13 |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 22 |
| Pregabalin | Pregabalin | 30 | 11 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 12 |
| Nitroglycerin | Nitroglycerin | 27 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | 14 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | 12 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Indomethacin | Indomethacin | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 21 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 11 |
| Glipizide | Glipizide | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.53 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, SHINGRIX, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error